Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia

Int J Infect Dis. 2021 Sep:110:338-340. doi: 10.1016/j.ijid.2021.07.064. Epub 2021 Jul 28.

Abstract

During the coronavirus disease 2019 (COVID-19) pandemic, patients with humoral immunodeficiency are at higher risk of developing chronic infection and having a negative outcome. Few data are available on therapeutic options for this population. This case report discusses the treatment of disease relapse with remdesivir and monoclonal antibodies in an adult patient with X-linked agammaglobulinaemia.

Keywords: COVID-19; Casirivimab; Imdevimab; Immunocompromised; Monoclonal antibodies; Neutralizing antibodies; Remdesivir; SARS-CoV-2; XLA.

Publication types

  • Case Reports

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Adult
  • Agammaglobulinemia
  • Alanine / analogs & derivatives
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 Drug Treatment*
  • Genetic Diseases, X-Linked
  • Humans
  • Recurrence
  • SARS-CoV-2*

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • remdesivir
  • Adenosine Monophosphate
  • Alanine

Supplementary concepts

  • Bruton type agammaglobulinemia